Use of Erdafitinib in FGFR3-Mutated Recurrent Respiratory Papillomatosis.

Abstract

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00435 JCO Precision Oncology no. 6 (2022) e2200435. Published online December 1, 2022. Use of Erdafitinib in FGFR3-Mutated Recurrent Respiratory Papillomatosis Vincent Yeung , MD1xVincent YeungSearch for articles by this author; Paul Sackstein , MD2xPaul SacksteinSearch for articles by this author; Nazaneen N. Grant, MD3xNazaneen N. GrantSearch for articles by this author; Rebecca Krochmal, MD4xRebecca KrochmalSearch for articles by this author; Nishant Gandhi, PhD5xNishant GandhiSearch for articles by this author; Charu Aggarwal , MD6xCharu AggarwalSearch for articles by this author; Balazs Halmos , MD7xBalazs HalmosSearch for articles by this author; Joshua E. Reuss , MD1xJoshua E. ReussSearch for articles by this author; Stephen V. Liu , MD1xStephen V. LiuSearch for articles by this author; and Chul Kim , MD1xChul KimSearch for articles by this author Show More 1Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC2Department of Internal Medicine, Georgetown University, Washington, DC3Department of Otolaryngology, Georgetown University, Washington, DC4Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Georgetown University, Washington, DC5Medical Affairs, Caris Life Sciences, Phoenix, AZ6Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA7Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY https://doi.org/10.1200/PO.22.00435 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: Vincent Yeung, Rebecca Krochmal, Charu Aggarwal, Stephen V. Liu, Chul KimAdministrative support: Chul KimProvision of study materials or patients: Chul KimCollection and assembly of data: Vincent Yeung, Nazaneen N. Grant, Nishant Gandhi, Stephen V. Liu, Chul KimData analysis and interpretation: Vincent Yeung, Paul Sackstein, Rebecca Krochmal, Nishant Gandhi, Balazs Halmos, Joshua E. Reuss, Stephen V. Liu, Chul KimManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Rebecca KrochmalHonoraria: Intuitive SurgicalTravel, Accommodations, Expenses: Intuitive SurgicalNishant GandhiEmployment: Caris Life SciencesCharu AggarwalConsulting or Advisory Role: Genentech, Lilly, Celgene, Merck, AstraZeneca, Blueprint Genetics, Shionogi, Daiichi Sankyo/Astra Zeneca, Sanofi/Regeneron, Eisai, BeiGene, Turning Point Therapeutics, Pfizer, Janssen, Boehringer IngelheimSpeakers' Bureau: AstraZeneca (I), Roche/Genentech (I)Research Funding: Genentech/Roche (Inst), Incyte (Inst), Macrogenics (Inst), Merck Sharp & Dohme (Inst), AstraZeneca/MedImmune (Inst)Balazs HalmosConsulting or Advisory Role: AstraZeneca, Boehringer Ingelheim, Genentech/Roche, Pfizer, Takeda, Novartis, Merck, Bristol Myers Squibb, Turning Point Therapeutics, Apollomics, Janssen Oncology, Veracyte, BeiGene, Arcus BiosciencesResearch Funding: Merck (Inst), AstraZeneca (Inst), Mirati Therapeutics (Inst), Boehringer Ingelheim (Inst), Roche/Genentech (Inst), Pfizer (Inst), Takeda (Inst), AbbVie (Inst), Bristol Myers Squibb (Inst), GlaxoSmithKline (Inst), Blueprint Medicines (Inst), Novartis (Inst), Advaxis (Inst), Janssen Oncology (Inst), Elevation Oncology (Inst), Amgen (Inst), BeiGene (Inst), Daiichi Sankyo/Astra Zeneca (Inst)Joshua E. ReussHonoraria: AstraZeneca/MedImmuneConsulting or Advisory Role: OncoCyte, Genentech/Roche, Sanofi, Personalis, Guardant HealthResearch Funding: Genentech/Roche (Inst), Verastem (Inst)Stephen V. LiuConsulting or Advisory Role: Genentech, Lilly, Bristol Myers Squibb, AstraZeneca, Takeda, Regeneron, Guardant Health, Janssen Oncology, MSD Oncology, Jazz Pharmaceuticals, Blueprint Medicines, Daiichi Sankyo/UCB Japan, BeiGene, Amgen, Turning Point Therapeutics, Elevation Oncology, Novartis, Eisai, Bayer, Gilead Sciences, SanofiResearch Funding: Genentech/Roche (Inst), Pfizer (Inst), Bayer (Inst), Merck (Inst), Blueprint Medicines (Inst), Lilly (Inst), Rain Therapeutics (Inst), Alkermes (Inst), Bristol Myers Squibb (Inst), Turning Point Therapeutics (Inst), RAPT Therapeutics (Inst), Merus (Inst), Elevation Oncology (Inst), Nuvalent, Inc (Inst), Gilead Sciences (Inst)Travel, Accommodations, Expenses: Caris Life SciencesChul KimConsulting or Advisory Role: Janssen, Novartis, PierianDx, AstraZeneca, Sanofi, Diffusion Pharmaceuticals, Mirati Therapeutics, Jazz Pharmaceuticals, Arcus BiosciencesResearch Funding: AstraZeneca, Novartis, Karyopharm Therapeutics, Bristol Myers Squibb, Regeneron, Debiopharm Group, Janssen, Genentech/RocheNo other potential conflicts of interest were reported.